Want to see AKTX full AI Analyst Report?
Top Page
Akari Therapeutics
(NASDAQ:AKTX)
Select Model
Select Model
Rating:42Neutral
Price Target:
$7.00
▼(-19.54% Downside)
Action:Reiterated
Date:08/18/26
The score is primarily weighed down by weak financial performance (no revenue, widening TTM losses, and continued cash burn) and bearish technicals (price below all key moving averages with negative MACD). Low leverage offers some stability, but declining equity and financing-related corporate actions keep dilution risk elevated, while valuation metrics provide little support given losses and no dividend yield.
Positive Factors
Low financial leverage
Minimal debt reduces interest obligations and refinancing exposure, giving Akari greater flexibility to allocate capital toward clinical development. This provides some balance-sheet resilience even though the company remains dependent on equity financing.
Negative Factors
No revenue and widening losses
The absence of revenue leaves Akari reliant on financing rather than operating cash generation, while widening losses indicate increasing pressure from development and corporate costs. Without successful commercialization, this weak earnings profile is likely to persist.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Minimal debt reduces interest obligations and refinancing exposure, giving Akari greater flexibility to allocate capital toward clinical development. This provides some balance-sheet resilience even though the company remains dependent on equity financing.
Read all positive factors
Akari Therapeutics (AKTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.16M
Dividend YieldN/A
Average Volume (3M)1.63M
Price to Earnings (P/E)―
Beta (1Y)1.38
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1600.00
Shares Outstanding1,144,588
10 Day Avg. Volume2,851,768
30 Day Avg. Volume1,628,756
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$28.50Price Target Upside227.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-8.01
Revenue Forecast (FY)N/A
Akari Therapeutics Business Overview & Revenue Model
Company Description
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell...
How the Company Makes Money
null...
Akari Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -31.59M | -17.35M | -19.53M | -10.00M | -17.74M | -17.42M |
| Net Income | -30.96M | -17.30M | -19.79M | -10.01M | -17.75M | -17.42M |
Balance Sheet | ||||||
| Total Assets | 38.62M | 47.89M | 50.56M | 4.36M | 13.83M | 11.65M |
| Cash, Cash Equivalents and Short-Term Investments | 7.69M | 5.20M | 2.60M | 3.85M | 13.25M | 9.36M |
| Total Debt | 693.00K | 754.00K | 3.26M | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 20.03M | 19.56M | 28.33M | 4.58M | 12.04M | 6.09M |
| Stockholders Equity | 18.59M | 28.33M | 22.23M | -229.00K | 1.79M | 5.55M |
Cash Flow | ||||||
| Free Cash Flow | -10.74M | -10.57M | -12.55M | -16.43M | -21.50M | -18.85M |
| Operating Cash Flow | -10.74M | -10.57M | -12.55M | -16.43M | -21.50M | -18.85M |
| Investing Cash Flow | -15.00K | 0.00 | 382.00K | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 15.72M | 13.17M | 10.99M | 7.02M | 25.29M | 14.29M |
Akari Therapeutics Technical Analysis
Negative
8.70
Price Trends
10.50
Negative
8.84
Negative
10.96
Negative
Market Momentum
-0.85
Negative
44.32
Neutral
71.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AKTX, the sentiment is Negative. The current price of 8.7 is above the 20-day moving average (MA) of 7.95, below the 50-day MA of 10.50, and below the 200-day MA of 10.96, indicating a bearish trend. The MACD of -0.85 indicates Negative momentum. The RSI at 44.32 is Neutral, neither overbought nor oversold. The STOCH value of 71.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AKTX.
Akari Therapeutics Risk Analysis
Akari Therapeutics disclosed 53 risk factors in its most recent earnings report. Akari Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Akari Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $343.02M | 3.04 | -6.74% | ― | -100.00% | 95.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $34.54M | -3.15 | -92.69% | ― | ― | 37.68% | |
45 Neutral | $11.82M | -0.04 | 3114.17% | ― | ― | 85.06% | |
42 Neutral | $13.16M | >-0.01 | -123.29% | ― | ― | ― | |
42 Neutral | $14.61M | -0.40 | -150.88% | ― | ― | 38.14% |
* Healthcare Sector Average
AKTX
Akari Therapeutics
7.90
-31.76
-80.08%
NNVC
NanoViricides
1.35
-0.09
-6.25%
MBRX
Moleculin Biotech
0.61
-14.29
-95.91%
PASG
Passage Bio
4.52
-2.40
-34.68%
SABS
SAB Biotherapeutics
3.79
1.79
89.50%
Akari Therapeutics Corporate Events
Executive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingShareholder Meetings
Akari Therapeutics shareholders approve key AGM resolutions
Positive
Jul 2, 2026
On June 30, 2026, Akari Therapeutics held its Annual General Meeting, where shareholders approved the 2025 financial statements, directors’ remuneration report and policy, and most director re-elections, while voting against the return of Ja...
Private Placements and FinancingShareholder Meetings
Akari Therapeutics Streamlines Private Placement Financing Tranches
Neutral
Jun 26, 2026
On May 22, 2026, Akari Therapeutics entered into a securities purchase agreement with certain investors for a private placement of 1,470,588 unregistered American Depository Shares or prefunded warrants, alongside Series H, Series I and Series J w...
Business Operations and StrategyPrivate Placements and Financing
Akari Therapeutics Announces Private Placement of Equity Securities
Neutral
May 22, 2026
On May 20, 2026, Akari Therapeutics entered into a securities purchase agreement with certain investors for a private placement of 1,470,588 unregistered American Depositary Shares, or pre-funded warrants in lieu of ADSs, bundled with Series H, I ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.